Xponance Inc. Has $11.59 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Xponance Inc. boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,272 shares of the biopharmaceutical company's stock after acquiring an additional 482 shares during the period. Xponance Inc.'s holdings in Regeneron Pharmaceuticals were worth $11,591,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Truvestments Capital LLC bought a new position in Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 15 shares during the last quarter. OFI Invest Asset Management bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $28,000. Finally, Larson Financial Group LLC boosted its holdings in Regeneron Pharmaceuticals by 127.3% in the third quarter. Larson Financial Group LLC now owns 50 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 28 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Down 0.6 %

REGN stock traded down $4.14 during mid-day trading on Friday, reaching $658.48. The company had a trading volume of 1,869,108 shares, compared to its average volume of 634,475. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a 50 day simple moving average of $689.43 and a two-hundred day simple moving average of $815.71. The company has a market capitalization of $71.99 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $11.86 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. Regeneron Pharmaceuticals's dividend payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on REGN shares. Bernstein Bank cut their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Robert W. Baird cut their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 5th. Citigroup cut their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 28th. Piper Sandler cut their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Finally, Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.